Research ArticleCancer

p95HER2–T cell bispecific antibody for breast cancer treatment

See allHide authors and affiliations

Science Translational Medicine  03 Oct 2018:
Vol. 10, Issue 461, eaat1445
DOI: 10.1126/scitranslmed.aat1445

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

  • RE: p95HER2–T cell bispecific antibody for breast cancer treatment
    • Dianne Sika-Paotonu, Associate Dean (Pacific)/Senior Lecturer Pathology & Molecular Medicine, Wellington School of Medicine & Health Sciences, University of Otago, New Zealand

    To the Editor,

    I read with very keen interest the article authored by Ruiz I.R., et al. (1) and entitled: “p95HER2-T cell bispecific antibody for breast cancer treatment.”

    This work describes the development of an engineered TCB known as p95HER2-T cell bispecific antibody, based on a carboxy-terminal fragment of HER2 expressed in a subset of HER2 tumours, that was able to demonstrate potent antitumor activity on p95HER2-expressing breast primary cancers and brain lesions.

    The p95HER2-T cell bispecific antibody facilitates contact between cancer cells and T cells with the purpose of enhancing antitumor immunity by ensuring appropriate crosslinking and engagement steps occur that trigger T cell activation and results in cancer cell killing.

    As p95HER2 is not expressed in normal tissues, its use as a target in this context confers a high degree of specificity which prevents the toxicity associated with the use of other treatments such as the monoclonal antibody trastuzamab that targets HER2 tumour cells, but causes side effects due to the expression of HER2 on normal epithelial tissues.

    The potential to increase the dose of the p95HER2-T cell bispecific antibody due to the high tumour-specificity of the p95HER2 antigen will be of tremendous benefit to ensure maximal antitumor benefit is achieved and side effects are limited.

    Overall an exciting set of results accentuating the development of safer and more effective breast cancer i...

    Show More
    Competing Interests: None declared.

Stay Connected to Science Translational Medicine

Navigate This Article